Can PTC get away with a $35,000 price tag on a cheap, old over­seas steroid for Duchenne?

PTC Ther­a­peu­tics $PTCT thinks it can roll out the steroid de­flaza­cort for $35,000 a year, un­der­cut­ting the $89,000 price that pushed Marathon Phar­ma­ceu­ti­cals to the cen­ter stage of a US drug pric­ing scan­dal.

The biotech bought de­flaza­cort from Marathon for $140 mil­lion in cash plus a pos­si­ble $50 mil­lion mile­stone, bet­ting that they could spring in­to the US mar­ket with the steroid. It’s been avail­able over­seas for about $1,000 a year, leav­ing the Duchenne par­ents who had been ac­quir­ing it for a low cost steam­ing over the in­flat­ed US price.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.